Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML.

Saved in:
Bibliographic Details
Title: Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML.
Authors: Tothova Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Cancer Program, Broad Institute, Cambridge, Massachusetts, USA., Valton AL; Program in Systems Biology, Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts, USA., Gorelov RA; Cancer Program, Broad Institute, Cambridge, Massachusetts, USA., Vallurupalli M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Cancer Program, Broad Institute, Cambridge, Massachusetts, USA., Krill-Burger JM; Cancer Program, Broad Institute, Cambridge, Massachusetts, USA., Holmes A; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Landers CC; Cancer Program, Broad Institute, Cambridge, Massachusetts, USA., Haydu JE; Cancer Program, Broad Institute, Cambridge, Massachusetts, USA., Malolepsza E; Cancer Program, Broad Institute, Cambridge, Massachusetts, USA., Hartigan C; Cancer Program, Broad Institute, Cambridge, Massachusetts, USA., Donahue M; Cancer Program, Broad Institute, Cambridge, Massachusetts, USA., Popova KD; Cancer Program, Broad Institute, Cambridge, Massachusetts, USA., Koochaki S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Venev SV; Program in Systems Biology, Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts, USA., Rivera J; Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom., Chen E; Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom., Lage K; Cancer Program, Broad Institute, Cambridge, Massachusetts, USA., Schenone M; Cancer Program, Broad Institute, Cambridge, Massachusetts, USA., D'Andrea AD; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Carr SA; Cancer Program, Broad Institute, Cambridge, Massachusetts, USA., Morgan EA; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Dekker J; Program in Systems Biology, Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.; Howard Hughes Medical Institute, Chevy Chase, Maryland, USA., Ebert BL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Cancer Program, Broad Institute, Cambridge, Massachusetts, USA.; Howard Hughes Medical Institute, Chevy Chase, Maryland, USA.
Source: JCI insight [JCI Insight] 2021 Feb 08; Vol. 6 (3). Date of Electronic Publication: 2021 Feb 08.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: Electronic Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2379-3708
DOI:10.1172/jci.insight.142149